The Goldman Sachs Group Increases Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $33.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target increased by The Goldman Sachs Group from $29.00 to $33.00 in a report published on Friday, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on AGIO. Royal Bank of Canada decreased their price target on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform rating for the company in a research report on Friday, February 16th. Cantor Fitzgerald reaffirmed an overweight rating on shares of Agios Pharmaceuticals in a report on Tuesday, April 9th. Finally, JPMorgan Chase & Co. reduced their price target on Agios Pharmaceuticals from $31.00 to $30.00 and set a neutral rating on the stock in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Hold and an average target price of $35.00.

Agios Pharmaceuticals Stock Down 3.8 %

Shares of AGIO opened at $33.22 on Friday. The stock has a market cap of $1.89 billion, a PE ratio of -5.26 and a beta of 0.81. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $35.50. The business has a 50-day simple moving average of $30.61 and a two-hundred day simple moving average of $25.76.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.20. The company had revenue of $8.19 million for the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. The business’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.47) earnings per share. On average, equities research analysts expect that Agios Pharmaceuticals will post -5.27 EPS for the current year.

Insider Buying and Selling

In other news, Director Jacqualyn A. Fouse sold 7,791 shares of Agios Pharmaceuticals stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total value of $214,642.05. Following the completion of the transaction, the director now directly owns 137,396 shares of the company’s stock, valued at approximately $3,785,259.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Jacqualyn A. Fouse sold 7,791 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $27.55, for a total transaction of $214,642.05. Following the completion of the sale, the director now owns 137,396 shares of the company’s stock, valued at $3,785,259.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the completion of the sale, the insider now owns 34,518 shares of the company’s stock, valued at $1,124,251.26. The disclosure for this sale can be found here. Insiders sold 16,035 shares of company stock valued at $475,277 over the last quarter. Insiders own 4.24% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AGIO. Nordea Investment Management AB raised its position in shares of Agios Pharmaceuticals by 13.0% during the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after purchasing an additional 30,764 shares during the period. Oak Ridge Investments LLC purchased a new position in Agios Pharmaceuticals in the first quarter valued at approximately $1,171,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Agios Pharmaceuticals by 0.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 314 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Agios Pharmaceuticals by 66.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,780 shares of the biopharmaceutical company’s stock worth $315,000 after purchasing an additional 4,311 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Agios Pharmaceuticals by 800.5% in the first quarter. Assenagon Asset Management S.A. now owns 454,801 shares of the biopharmaceutical company’s stock worth $13,298,000 after purchasing an additional 404,297 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.